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Abstract
The Department of Pediatric Cardiology, Medical University of Silesia in Katowice-Ligota,
studied 24 patients with clinically diagnosed (using ECG) long-QT syndrome (LQTS) in 18 cases.
Nine patients were diagnosed with LQT1 and nine with LQT2. The other six individuals were
healthy, with no symptoms characteristic for prolonged QT syndrome, but came from families
with confirmed disease occurrence. The study was conducted on members of four families. In
order to search for mutations (using mSSCP and sequencing), genomic DNA was obtained
from patients to determine the expression levels of the genes KCNQ1 and KCNH2 (HERG),
involved in the occurrence of clinical signs of disease. Total RNA was extracted from peri-
pheral blood. Consent to the use of blood samples of patients had been given by the Bioethics
Commission of the Medical University of Silesia.
mSSCP analysis and sequencing did not confirm the occurrence of mutations in KCNQ1 and
HERG associated with the occurrence of LQTS. Analysis of gene expression profile of KCNQ1
and HERG confirmed the presence of disease in people with a known clinical diagnosis.
Overexpression, as well as reduced expression, was observed for the examined genes. KCNQ1
was inhibited in two families, whereas HERG was reduced in one and overexpressed in the
other. Gene expression profile analysis showed abnormal expressions of KCNQ1 and HERG
in healthy subjects, which may be a sign of predisposition to develop the disease. The novelty of
our study involved the use of total mRNA isolated from human peripheral blood, and the very
limited evidence in the literature to date regarding the assessment of gene expression profile of
HERG and KCNQ1 in relation to the presence of prolonged QT syndrome. (Cardiol J 2012;
19, 2: 159–167)
Key words: long-QT syndrome, molecular diagnostics, QRT-PCR (real-time PCR),
mSSCP analysis, sequence analysis
Introduction
Congenital prolonged QT syndrome is a rare
genetically determined disease associated with
impaired function or structure of ion channels lo-
cated in the heart. This results in abnormal cardiac
repolarization and the risk of the appearance of car-
diac arrhythmias and sudden cardiac death (SCD).
Characteristics are: prolonged QT interval in the
ECG, the incidence of syncope, and sudden cardiac
arrest [1, 2]. To date, 12 genes have been disco-
vered, mutations of which are responsible for long
QT syndrome (LQTS). All candidate genes are lo-
cated on autosomes, which explains the lack of di-
sease association with sex. The genes, mutations
of which cause LQTS1 i.e. KvLQT1, KCNQ1, and
LQTS2 i.e. HERG-KNNH2, encode proteins of po-
tassium channels, while LQTS3 (SCN5A) is caused
by mutations in the gene encoding the sodium chan-
nel protein [3, 4].
160
Cardiology Journal 2012, Vol. 19, No. 2
www.cardiologyjournal.org
The primary goal of treatment is to prevent the
LQTS episodes of arrhythmias and sudden cardiac
arrest. Beta-blockers are commonly used as drugs
of choice for all patients with LQTS, but the intro-
duction of therapy, depending on the patient’s geno-
type, has proved to be useful in the treatment of
various types of LQTS. In LQTS1, nikorandil is
applied, which shortens the QT interval. In LQTS2,
due to the large loss of potassium, spironolactone
and potassium salts are used. In LQTS3, antiar-
rhythmic drugs such as lidocaine, mexiletine, and
flecainide have proved effective [1, 3, 5]. In situa-
tions where treatment with b-blockers appears to
be ineffective, LQTS3 patients are recommended
for cardioverter-defibrillator implantation [6].
There have been reports that 50–60% of pa-
tients with LQTS have the LQTS1 genotype, 35–
–40% the LQTS2 genotype, and 8% the LQTS3 geno-
type. Mutations in LQTS1 and LQTS2 are associa-
ted with an earlier manifestation of symptoms and
a low risk of sudden death, whereas LQTS3 muta-
tions are connected with the later appearance of
symptoms and a higher risk of SCD [7]. Due to the
frequent absence of clinical symptoms in up to 40%
of carriers of mutant genes, which do not always
verify the clinical diagnostic criteria, these patients
should be diagnosed using molecular methods.
The early identification of LQTS is important
because of the high mortality in untreated patients
with symptoms (20% of patients die within one year
of the first loss of consciousness, and 50% of pa-
tients have died ten years after such an episode)
[3, 7]. Carriers of mutations in whom the disease
has not been revealed have a 10% risk of arrhyth-
mia before the age of 40, especially when addition-
ally taking QT prolonging drugs or when they are
exposed to factors that initiate cardiac arrhythmias
[8]. In asymptomatic carriers of mutations, geno-
typic identification has some limitations because not
all mutations that cause LQTS are recognizable in
a genotype [7].
Molecular analysis
Clinical characteristics of patients
In our study, we called the four families: fami-
ly 1, family 2, family 3 and family 4.
Among the eight members of family 1, of three
different generations, only one person was not stu-
died. After performing an electrocardiogram (ECG),
it turned out that all the women in this family suf-
fered from LQTS1. Clinical examination also con-
firmed the presence of LQTS1 in a male child of
a sick mother and a healthy father.
The entire two-generation family 2 underwent
study (four persons). LQTS1 was diagnosed by ECG
in the father and his two children, but the mother
was healthy.
The four-generation 11–member family 3 was
diagnosed by ECG: LQTS2 symptoms were re-
vealed in four patients, and two patients from the
first generation were not analyzed. Two sisters
from the second generation were healthy. Two of
the three children of one of these sisters were sick,
but their biological father did not suffer from
LQTS2. In the last studied generation, the disease
was present in all descendants of a sick mother and
a healthy father.
In the three-generation family 4, of six indivi-
duals, five were examined. All patients from family
4 were diagnosed with LQTS2.
The pedigrees of the four families are shown
in Figure 1.
The study was approved by the local bioethical
committee and all patients gave their informed consent.
Qualitative assessment of total RNA extracts
In order to analyze the quality, DNA and RNA
extracts were analyzed using the technique of elec-
trophoresis in 1% agarose gel stained with ethi-
dium bromide.
Quantitative assessment of DNA
and RNA extracts
Genomic DNA was obtained from 5 mL of
whole blood using proteinase K and universal lysis
buffer, while total RNA (from 1 mL of whole blood)
was extracted using phenosol, chloroform and iso-
propanol. Quantitative assessment was made using
a calculator GeneQuant Pro (Amersham Biosiences).
The absorbance of samples was measured at wave-
lengths of 260 nm and 280 nm. Absorbance at 260 nm
was associated with a concentration of DNA and
RNA in the samples. Furthermore, the purification
factor (ratio of absorbance A280nm/A260nm) was
detemined. The highest concentration of RNA was
observed in patient number 30. It was 0.428 µg/µL.
Patient number 30 belonged to a group of indivi-
duals diagnosed with LQTS. The lowest concentra-
tion of RNA was observed in patient number 105:
0.040 µg/µL. This patient also was diagnosed with
the disease. The average value of RNA concentra-
tion was 0.110 ± 0.082 µg/µL. The purity factor av-
eraged 1.544 ± 0.160. The maximum value of the ex-
tract concentration of RNA in patients diagnosed
clinically was 1.428 µg/µL, and the minimum was
0.040 µg/µL. The average concentration was 0.111 ±
± 0.091 µg/µL, while the purification average rate
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was 1.528 ± 0.095. The value of the maximum con-
centration of RNA in the group of healthy subjects
was 0.202 µg/µL, and the minimum was 0.064 µg/
/µL. The average concentration of total RNA was
0.105 ± 0.051 µg/µL, and was 0.006 µg/µL lower
than in the diagnosed patients. The average purity
ratio was 1.590 ± 0.234 and was 0.061 higher than
in the group diagnosed with LQTS. The highest con-
centration of DNA was observed in patient number 30,
who was diagnosed with the disease. This was
0.115 µg/µL. The lowest concentration of DNA was
recorded in patient number 45 and was 0.018 µg/µL.
This patient belonged to a group of people dia-
gnosed with LQTS. The average value of concen-
tration was 0.042 ± 0.022 µg/µL. The purity coeffi-
cient averaged 1.922 ± 0.338. The value of the maxi-
mum concentration of DNA extract in patients
diagnosed clinically was 0.115 µg/µL, and the min-
imum was 0.018 µg/µL. The average concentration
was 0.041 ± 0.024 µg/µL, while the purification
average rate was 1.868 ± 0.230. The value of the
maximum concentration of DNA in the group of
healthy subjects was 0.074 µg/µL, and the minimum
was 0.025 µg/µL. The average concentration of to-
tal DNA was 0.042 ± 0.020 µg/µL, and was 0.018
lower than in diagnosed patients. The average pu-
rity ratio was 2.083 ± 0.552 and was 0.214 higher
than in the group diagnosed with LQTS.
Assessment of the size of PCR products
Extracts were subjected to genomic DNA am-
plification. Using polyacrylamide gel electrophore-
sis, the sizes of amplification reaction products were
assessed. Polyacrylamide gel was then stained and
analyzed by gel documentation system BASSYS1D
(Biotec Fischer) and GelScan v.1.45 (Kucharczyk).
The size of each product was evaluated by compar-
ing its electrophoretic mobility and the mobility of
restriction fragment pattern of plasmid pBR322
digested with HaeIII endonuclease. Statistical ana-
lysis was performed for all PCR products in order
to verify the assumptions of equal value and the
average band to determine the error in the calcula-
tion of the gel documentation system (results not
shown). Amplified fragments of the studied genes
were separated and submitted to polyacrylamide
Figure 1. Pedigrees of surveyed families. Circles indicate females, squares indicate males. Sample number shown in
normal font. Age of family members shown in italics. Grey color symbolizes the disease, while white stands for
healthy person. Question mark means that the person was not subjected to the test.
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gel. The specificity of the reaction was confirmed
on densitometric analysis of PCR products, on the
basis of the position of bands, also referred to the
size of each amplification product (expressed in
quantities of base pairs).
Analysis of HERG and KCNQ1
genes using mSSCP technique
To establish the prevalence of mutations or
polymorphisms in the studied patients, both those
with LQTS and those who were healthy, mSSCP
analysis of individual exons of KCNQ1 and HERG
genes was performed according to the procedure
described previously. The figures in this study show
the polyacrylamide gels after mSSCP analysis of
HERG and KCNQ1 genes with clearly visible bands,
which illustrates the correct expression of the de-
natured samples and appropriately selected condi-
tions of electrophoretic separation.
Figure 2 shows the results of mSSCP analysis
of exon 3 of HERG gene for 14 patients. Paths 1–14
contain dsDNA and ssDNA fragments of HERG
gene. dsDNA, which migrates faster, is visible at
the bottom of the gel (240 bp), whereas the ssDNA
fragments are located above. The fact that all the
ssDNA bands are located at the same height in all
cases shows the lack of mutations or polymor-
phisms in the material. Path 15 contains control
native HERG gene PCR product (negative control),
and track 16 contains the size marker (pBR322/
/HaeIII) (Fig. 2). mSSCP analysis of exon 3 of HERG
gene identified the following location of ssDNA
bands: 504 bp + 439 bp + 382 bp + 327 bp. The
presence of four bands in this case indicates the
heterozygosity (Fig. 2).
Figure 3 shows the results of mSSCP analysis
of exon 6 of KCNQ1 gene for 14 patients. In each
track (1–15) there was non-denaturated PCR product
(negative control) and in the last track (16) there was
a size marker (pBR322/HaeIII). Gel obtained for
KCNQ1 gene exon 6 revealed the presence of two
ssDNA bands, their position was as follows: 599 bp +
+ 448 bp. The presence of two bands indicates
homozygosity of the test sequence. The fact that
all the ssDNA bands are located at the same height
in all cases is associated with a lack of mutations or
polymorphisms in the material (Fig. 3).
Sequencing analysis
of genes KCNQ1 and HERG
In order to exclude or confirm the presence
of mutations or polymorphisms in the patients
studied, sequencing analysis was performed accor-
ding to the previously described procedure. This
analysis aimed to identify mutations (mSSCP,
sequencing) which had not been confirmed as
present in the families enrolled in the study. In the
analysis of nucleotide sequence, all the genes test-
ed were identical to gene sequences obtained from
genetic databases, suggesting a lack of mutations
in the studied genes (ENSG00000053918 and
ENSG00000055118).
Figure 2. mSSCP analysis of HERG exon 3 (heterozygous). Tracks 1–14: Bands 1–4 — ssDNA; Band 5 — dsDNA (PCR
product size undenatured 240 bp). Track 15: Native PCR product. Track 16: Pattern (plasmid pBR322 digested with
HaeIII endonuclease).
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Pattern
587 bp
540 bp
504 bp
458 bp
434 bp
267 bp
234 bp
213 bp
192 bp
184 bp
124 bp
104 bp
89 bp
80 bp
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Analysis of the expression
of genes KCNQ1 and HERG
We analyzed two genes responsible for the
occurrence of LQTS1 and LQTS2. We proved both
overexpression and reduced expression of the
genes examined. For the families surveyed, five
values were calculated: the median, lower and up-
per quartile, the mean, and standard deviation. The
results are shown in Table 1. The average value of
the number of copies of KCNQ1 mRNA in family 1
was 9,364 ± 22,789.5. People diagnosed with
LQTS1 presented reduced expression of KCNQ1.
A healthy person also had a smaller number of co-
pies of KCNQ1 mRNA. For family 2, the gene copy
number ranged from 214 to 1,082. In patients with
clinically confirmed disease, there was a significant
reduction in KCNQ1 gene expression. The average
value of the test gene copy number was 620 ±
± 396.8.
In family 3, the highest value of HERG gene
expression (2,146,723 copies) was present in a pa-
tient diagnosed with LQTS. In all patients suffer-
ing from LQTS2, we clearly observed increased
expression of the gene (in one patient only slightly
elevated). The average value of KCNE2 gene copy
number was 651,948 ± 941,692.
All members of family 4 had a reduced expres-
sion of HERG, but their values were different,
which may be associated with symptoms in indivi-
dual patients. Gene occurred in this family with an
average number of copies of 1,330 ± 2,763.6.
Figure 3. mSSCP analysis of KCNQ1 exon 6 (homozygous). Tracks 1–14: Bands 1–2 — ssDNA; band 3 — dsDNA
(PCR product size undenatured 240 bp). Track 15: Native PCR product. Track 16: Pattern (plasmid pBR322 digested
with HaeIII endonuclease).
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Pattern
587 bp
540 bp
504 bp
458 bp
434 bp
267 bp
234 bp
213 bp
192 bp
184 bp
124 bp
104 bp
Table 1. Descriptive statistics of families 1–4
(both sick and healthy taken into account).
Parameter KCNQ1 b-actin
Family 1
Median 726 3,427
Lower quartile 429.0 2,355.2
Upper quartile 1,414.9 660,715.6
Mean deviation 9,364 605,940.0
Standard deviation 22,789.5 1,125,933.0
Family 2
Median 593.0 43,277.0
Lower quartile 336.6 24,056.6
Upper quartile 876.0 101,195.0
Mean deviation 620.0 81,975.0
Standard deviation 396.8 106,968.7
Family 3
Median 204,965.0 8,913.0
Lower quartile 104,441.1 3,948.0
Upper quartile 717,817.3 11,151.0
Mean deviation 651,948.0 12,595.0
Standard deviation 941,692.0 15,710.3
Family 4
Median 94.0 75,687.0
Lower quartile 2,763.7 51,821.0
Upper quartile 224.3 150,172.8
Mean deviation 1,330.0 160,476.0
Standard deviation 2,763.7 210,091.2
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Discussion
Four families were tested, totaling 24 people:
nine patients with LQTS1, nine with LQTS2, and
six healthy. The family members were patients of
the Pediatric Cardiology Medical University of Sile-
sia in Katowice-Ligota. From the peripheral blood,
total RNA and genomic DNA were isolated. The
average value of the total RNA concentration was
0.110 ± 0.082 µg/µL, with a coefficient purity of
1.544 ± 0.160, which was lower than the value de-
scribed in the literature [9]. This may result from
phenol contamination of samples or insufficient dry-
ing time, or storing blood for too long. The average
value of the concentration of DNA extracts was
0.042 ± 0.022 µg/µL, with a coefficient purity of
1.922 ± 0.338, which was higher than described in
the literature [10]. This may indicate contamination
as with the RNA. Genomic DNA was used to am-
plify exons 1–6 of KCNQ1 and 1–15 of HERG gene.
We present the results of analysis for exons 2–7 of
KCNQ1 gene, encoding a subunit of the slowly ac-
tivating potassium channel and exons 6–9 of HERG
encoding a subunit of the rapidly activating potas-
sium channel.
We analyzed exons using two techniques:
mSSCP and sequencing method. This paper pre-
sents the results for the HERG gene exon 3 and
exon 6 of gene KCNQ1. Literature data indicates
that these methods are useful in detecting polymor-
phisms and mutations in genes associated with the
occurrence of LQTS [2, 12–18].
In this work, we used a variation of the SSCP
technique known as mSSCP (multitemperature
SSCP) due to its simplicity, greater sensitivity, re-
duced cost and time analysis. mSSCP analysis of
HERG and KCNQ1 revealed no mutations in these
genes. We showed heterozygosity of HERG gene
exon 3, visible as a pattern composed of four bands
that are the equivalent of ssDNA, which indicates
acceptable polymorphism in the nature rather than
a mutation. Analysis of exon 6 of gene KCNQ1 indi-
cated its homozygotic sequence (two bands ssDNA).
Other investigators from Medical University of
Silesia (MUS) have described similar results [2].
By analyzing six exons of the gene KCNQ1 they
gained a wider spectrum of fringe patterns, con-
firmed the homozygosity and heterozygosity and
lack of sequence mutation. The size of tested DNA
fragments has a huge impact on the analysis sensi-
tivity. The best results are achieved with a size of
150 bp, where the detection of changes reaches
more than 95%. Above 300 bp, detection falls be-
low 80% [19]. In this paper, the length of ssDNA
fragments was 250–350 bp, so the mSSCP analysis
could not reveal conformational variants of ssDNA
providing a possible mutation. An important para-
meter is the temperature of the electrophoresis,
which should not exceed 20°C, because it has
a negative effect on the efficiency of creating con-
formers. The use of simultaneous electrophoresis
at different temperatures increases the sensitivity
of the method [2, 19]. In this paper, we used tem-
peratures of 4oC, 10oC, and 25oC. The heat may
cause the formation of unstable conformers, which,
during electrophoresis, pass from one form to ano-
ther, which is evident in the form of fuzzy bands and
streaks [19]. This effect was not observed in this
work. Sequencing is a method common among re-
searchers dealing with LQTS [2, 11, 12, 15, 20–24].
The result of sequencing confirmed the absence of
mutations in the analyzed genes. However, the ex-
clusion of mutations in studied patients may not be
definitive, because they might be present in the beta
subunits of studied genes, which were not analyzed.
RNA material after isolation and quantitative
and qualitative assessment was used as a template
for QRT-PCR reactions to evaluate the transcrip-
tional activity of genes tested by the number of cop-
ies of genes per 1 µg of total RNA.
The study revealed overexpression, and reduc-
tion in expression, of genes in LQTS patients and
in healthy subjects. In family 1, reduced expression
of KCNQ1 was detected. The average number of
KCNQ1 mRNA copies was 9,364 ± 22,789.52. For
b-actin gene it was 605,940 ± 1,125,933.
Reduced copy number of KCNQ1 gene was also
observed in family 2. The average number of mRNA
copies was 620 ± 396.8359951 (b-actin-81975 ±
± 106,968.7). KCNQ1 gene encodes the protein
transmembrane b subunit of slowly activating po-
tassium channel (Iks). Insufficient copy number of
KCNQ1 mRNA can lead to decreased translation of
protein building potassium channel or result in an
incomplete canal (built only with b subunit), which
may lead to impaired cardiac repolarization or the
abnormal transport of ions between the epithelial
cells in various tissues [25].
HERG overexpression was identified in fami-
ly 3. The average value of its gene mRNA copy
number was 651,948 ± 941,691.98, while the b-ac-
tin was 12,595 ± 15,710.28. Both clinically reco-
gnized and healthy patients showed an increased
number of HERG mRNA copies. This suggests an
increased predisposition to illness or possible mu-
tation carrier. HERG gene expression product is
a protein forming a subunit of rapid potassium chan-
nel (IKr), which is responsible for the final phase
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of repolarization in cardiomyocytes and for the pre-
vention of premature stimulation of myocardial in-
farction. Due to the PAS (Per-Arnt-Sim) conserva-
tive region presence in N-terminal fragment of pro-
tein, which is responsible for regulating the process
of deactivation of the channel, HERG overexpres-
sion (too much protein-forming subunit a) can af-
fect this process [26].
In family 4, where all members were diagnosed
with LQTS2, we observed a reduced number of copies
of the gene HERG mRNA. The average value of the
mRNA copy number was 1,330 ± 2,763.691079 and
was significantly lower than the number of copies
of b-actin mRNA 160,476 ± 210,091.2. The relation-
ship between the reduced number of HERG mRNA
copies and IKr operation may be responsible for
abnormal repolarization of myocardial cells, too fast
depolarization and lack of inhibition of early induced
arrhythmias [26]. Results showed a reduction in the
KCNQ1 expression in both analyzed families.
What may be surprising is a smaller number of
copies of this gene also in healthy subjects. This
raises a suspicion as to the increased predisposi-
tion of these individuals to the disease, but this
hypothesis requires further study. In family 3,
which revealed overexpression of the HERG gene,
healthy subjects had a larger number of gene co-
pies, which could be similarly interpreted.
Finley et al. [27] analyzed the expression le-
vels of KCNQ1 and HERG in horse cardiomyocytes.
mRNA molecules were obtained from the ventri-
cle and auricle cells of the heart. Different expres-
sion levels of the studied genes were proven. In
addition, expression levels of these genes were
compared in horse, rat and ferret. The outcome was
similar in all species (detected as increased num-
ber of copies of HERG mRNA) [27]. In 2008, [28]
University of Montreal researchers analyzed the
level of expression and tissue distribution of HERG
and KCNQ1 transcripts. They used commercially
available cell lines, including human embryonic kid-
ney cells, heart muscle cells, prostate cancer cells
and breast cancer cells. Using QRT-PCR reactions,
they confirmed the high level of expression of genes
KCNQ1 and HERG in cells of the pancreas, heart
and colon, whereas they found low levels in breast
cancer cells and cardiac muscle cells. They ob-
served a higher level of expression of these genes
in the right ventricle and right atrium of the heart
compared to the left ventricle and left atrium [28].
The most recent advances in research on
KCNQ1 and HERG expression were presented by
researchers from MUS [29]. As one of the first they
used the whole blood as a material for expression
analysis. KCNQ1 and HERG mRNA copy numbers
were significantly lower in healthy women than in
healthy men. Comparison of transcriptional activi-
ty of these genes studied in healthy adults and chil-
dren revealed a significantly higher number of
KCNQ1 mRNA copies and a lower number of HERG
mRNA copies in healthy adults [29]. Studies have
shown extremely high levels of KCNQ1 mRNA and
lower levels of HERG mRNA in adult patients aged
under 55 compared to the group aged over 55.
These results allow the conclusion that the differ-
ences in the expression of these genes are influ-
enced by the age and sex of respondents [29].
In subsequent studies, researchers from MUS
[30] evaluated the effect of the expression level of
KCNQ1 and HERG on disease occurrence. There
was no relationship between mRNA copy numbers
of studied genes and QT interval in patients with
LQTS1. A negative correlation was observed be-
tween the number of KCNQ1 mRNA copies and
QT interval in patients with LQTS2. The number
of copies of HERG mRNA had no effect on QT in-
terval in patients with LQTS2. The reason for this
could be the very small number of both patients and
healthy subjects in the study group and that the
disease among young people could still be undis-
closed. The study demonstrated that symptomatic
LQTS1 patients have statistically a much higher
number of KCNQ1 mRNA copies than those who
are asymptomatic (i.e. the healthy) [30].
In our work, there was no difference in expres-
sion between healthy and sick people, and there-
fore it cannot be compared. Both sick and healthy
patients have a similar (reduced) expression of
KCNQ1 gene, which may result from the carrier of
mutation or evidence of predisposition to disease.
In LQTS2, researchers have found higher levels of
HERG gene expression in symptomatic compared
to asymptomatic patients, but this difference was
not as significant as in the case of LQTS1. Both
hypotheses have to be confirmed in the future on
a larger number of patients [30]. Our work did not
confirm differences in expression between healthy
and sick people, and therefore it cannot be com-
pared.
Gene expression analysis of KCNQ1 and
HERG is ongoing, and the full picture is not yet
understood. Advances in molecular biology in the
diagnosis of LQTS tend to consider other factors
that may affect the phenotypic demonstration of
disease [22]. Doubt on this subject surrounds the
source from which the material is obtained for ge-
netic analysis. It is suspected that myocardial tis-
sue might be more appropriate than peripheral
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blood to study the expression of genes responsible
for LQTS. At present, studies are being conducted
to assess the suitability of a peripheral blood test
to evaluate the expression of these genes [22].
Based on the accumulated results, the impact of the
level of expression of KCNQ1 and HERG on the
occurrence of LQTS cannot be clearly identified. To
improve the results of the analysis, it would be
worth considering the acquisition of genetic mate-
rial from biopsies obtained from heart muscle cells.
Possible limitations of the current study result
from the fact that changes in gene expression are con-
trolled by complex, nonlinear interactions between
proteins, DNA, RNA and various metabolites. Analy-
sis of gene expression using the QRT-PCR technique
allows for the determination of the level of mRNA
expression (gene copy number/per the µg of protein),
but this method can only suggest possible changes in
the concentration of the protein or its function. The
expression of protein (protein concentration) may not
correlate with the expression of mRNA.
Despite the existence of a direct correlation
between gene expression and function of proteins,
further analysis, e.g. analysis of proteins, will be
necessary to clarify the role of the level of KCNQ1
and KCNH2 expression in the etiology of LQTS.
Another limitation is that the tested gene has to be
transcribed at detectable levels in available tissue
samples. Myocardial biopsy is not routinely per-
formed in the diagnosis of LQTS. Unigene Nation-
al Center for Biotechnology Information and Gene
Expression Omnibus suggest that the expression
of KCNH2 and KCNQ1 is limited to the heart mus-
cle, and their mRNA transcripts cannot be obtained
from lymphocyte cultures. Miller et al. [22] dem-
onstrated that cardiac-specific mRNA could be de-
tected in peripheral blood without additional puri-
fication steps or cell culture and used as starting
material for the study of mutations of genes asso-
ciated with heart disease.
It will be important to conduct studies to repli-
cate our observations. The estimation of single
nucleotide polymorphisms in genes associated with
LQTS [31] may also be a point of interest. Tomás
et al. [32] reported that the NOS1AP gene polymor-
phism, correlating with QT prolongation in a popu-
lation, plays a role in modulating the phenotypic
presentation in patients with LQTS.
Conclusions
1. mSSCP analysis results and sequencing did not
confirm the occurrence of KCNQ1 and HERG
mutations in the studied group of people.
2. Analysis of gene expression profile of KCNQ1
and HERG confirmed the presence of disease
in people with a known clinical diagnosis.
3. Overexpression was observed, as well as re-
duced expression, of the examined genes.
KCNQ1 showed reduced expression in two fa-
milies, whereas HERG expression was redu-
ced in one family and elevated in the other.
4. Gene expression profile analysis showed ab-
normal expression of KCNQ1 and HERG in
healthy subjects. This may suggest a predispo-
sition to develop the disease.
5. In order to obtain a more reliable picture of the
impact of tested genes expression on the pre-
sence of LQTS1 or LQTS2, it would be advisa-
ble to increase the number of people in the stu-
dy group.
6. The novel feature of our study was to use total
mRNA isolated from human peripheral blood
and a very limited literature knowledge regar-
ding the assessment of gene expression profi-
le of HERG and KCNQ1 in relation to the pre-
sence of prolonged QT syndrome.
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